Table 2.
Characteristics of infused HIV-specific and CMV-specific CD8+ T cells
| Patient | Clone specificity | Epitope | HLA restriction | Corresponding multimer | Vβ usage |
|---|---|---|---|---|---|
| HIV-specific CD8+ T cells | |||||
| 7701 | HIV-GAG | GEIYKRWII | HLA B*0801 | B*0801/GEIYKRWII- HIV-GAG | Vβ13 |
| 7702 | HIV-GAG | GEIYKRWII | HLA B*0801 | B*0801/GEIYKRWII- HIV-GAG | Vβ13 |
| 7703 | HIV-GAG | GEIYKRWII | HLA B*0801 | B*0801/GEIYKRWII- HIV-GAG | Vβ2 |
| 7704 | HIV-RT-POL | ILKEPVHGV | HLA A*0201 | A*0201/ILKEPVHGV-HIV-RT-POL | Vβ3 |
| 7705 | HIV-ENV | IPRRIRQGL | HLA B*0702 | B*0702/IPRRIRQGL-HIV-ENV | Vβ14 |
| 7707 | HIV-NEF | QVPLRPMTYK | HLA A*0301 | A*0301/QVPLRPMTYK-HIV-NEF | Vβ6 |
| 7709 | HIV-GAG | KRWIILGLNK | HLA B*2705 | B*2705/KRWIILGLNK-HIV-GAG | Vβ13 |
| CMV-specific CD8+ T cells | |||||
| 7701 | CMV-pp65 | NLVPMVATV | HLA A*0201 | A*0201/NLVPMVATV-CMV-pp65 | Vβ8 |
| 7702 | CMV-pp65 | NLVPMVATV | HLA A*0201 | A*0201/NLVPMVATV-CMV-pp65 | Vβ3 |
| 7703 | CMV-pp65 | NLVPMVATV | HLA A*0201 | A*0201/NLVPMVATV-CMV-pp65 | V8 |
| 7704 | CMV-pp65 | IPSINVHHY | HLA B*3501 | B*3501/IPSINVHHY-CMV-pp65 | Vβ3/13 |
| 7705 | CMV-pp65 | RPHERNGFTVL | HLA B*0701 | B*0701/RPHERNGFTVL-CMV-pp65 | Vβ12 |
| 7707 | CMV-pp65 | IPSINVHHY | HLA B*3501 | B*3501/IPSINVHHY-CMV-pp65 | Vβ1 |
| 7709 | CMV-pp65 | YSEHPTFTSQY | HLA A*0101 | A*0101/YSEHPTFTSQY-CMV-pp65 | Vβ13 |